Why Revelation Biosciences Stock Jumped Today as Traders Eye Its Kidney-Drug Bet
Revelation Biosciences shares rose 5.8% to $1.09 Wednesday, outpacing the Nasdaq. No new company news was released; the last update was May 11. Investors will vote June 24 on a reverse stock split. The company reported $14.1 million in cash at March 31 and aims to start a Phase 2/3 trial of its lead drug for acute kidney injury in the fourth quarter.